These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22439666)

  • 1. A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial.
    Berger AK; von Gall C; Abel U; Delorme S; Kloor M; Ose J; Weber TF; Stange A; Haag GM; Haberkorn U; Lordick F; Jäger D
    BMC Cancer; 2012 Mar; 12():108. PubMed ID: 22439666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab.
    Di Fabio F; Pinto C; Rojas Llimpe FL; Fanti S; Castellucci P; Longobardi C; Mutri V; Funaioli C; Sperandi F; Giaquinta S; Martoni AA
    Gastric Cancer; 2007; 10(4):221-7. PubMed ID: 18095077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial.
    Berger AK; Lücke S; Abel U; Haag GM; Grüllich C; Stange A; Dietrich M; Apostolidis L; Freitag A; Trierweiler C; von Gall C; Ose J; Giesel F; Weber TF; Lordick F; Haberkorn U; Jäger D
    Br J Cancer; 2018 Jul; 119(2):170-175. PubMed ID: 29961759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early prediction by 18F-FDG PET/CT for progression-free survival and overall survival in patients with metastatic colorectal cancer receiving third-line cetuximab-based therapy.
    Liu FY; Yen TC; Wang JY; Yang TS
    Clin Nucl Med; 2015 Mar; 40(3):200-5. PubMed ID: 25608159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
    Skougaard K; Nielsen D; Jensen BV; Hendel HW
    J Nucl Med; 2013 Jul; 54(7):1026-31. PubMed ID: 23572497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early
    Skougaard K; Nielsen D; Jensen BV; Pfeiffer P; Hendel HW
    Acta Oncol; 2016; 55(9-10):1175-1182. PubMed ID: 27548393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab.
    Wadlow RC; Hezel AF; Abrams TA; Blaszkowsky LS; Fuchs CS; Kulke MH; Kwak EL; Meyerhardt JA; Ryan DP; Szymonifka J; Wolpin BM; Zhu AX; Clark JW
    Oncologist; 2012; 17(1):14. PubMed ID: 22210091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography.
    Achmad A; Hanaoka H; Yoshioka H; Yamamoto S; Tominaga H; Araki T; Ohshima Y; Oriuchi N; Endo K
    Cancer Sci; 2012 Mar; 103(3):600-5. PubMed ID: 22126621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early 18F-FDG PET/CT Evaluation Shows Heterogeneous Metabolic Responses to Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer.
    van Helden EJ; Hoekstra OS; Boellaard R; Roth C; Mulder ER; Verheul HM; Menke-van der Houven van Oordt CW
    PLoS One; 2016; 11(5):e0155178. PubMed ID: 27196139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3'-Deoxy-3'-
    Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
    Lorenzen S; von Gall C; Stange A; Haag GM; Weitz J; Haberkorn U; Lordick F; Weichert W; Abel U; Debus J; Jäger D; Münter MW
    BMC Cancer; 2011 Jun; 11():266. PubMed ID: 21702914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer.
    Manning HC; Merchant NB; Foutch AC; Virostko JM; Wyatt SK; Shah C; McKinley ET; Xie J; Mutic NJ; Washington MK; LaFleur B; Tantawy MN; Peterson TE; Ansari MS; Baldwin RM; Rothenberg ML; Bornhop DJ; Gore JC; Coffey RJ
    Clin Cancer Res; 2008 Nov; 14(22):7413-22. PubMed ID: 19010858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab.
    Lastoria S; Piccirillo MC; Caracò C; Nasti G; Aloj L; Arrichiello C; de Lutio di Castelguidone E; Tatangelo F; Ottaiano A; Iaffaioli RV; Izzo F; Romano G; Giordano P; Signoriello S; Gallo C; Perrone F
    J Nucl Med; 2013 Dec; 54(12):2062-9. PubMed ID: 24136935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 111In-cetuximab-F(ab')2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model.
    van Dijk LK; Boerman OC; Franssen GM; Kaanders JH; Bussink J
    J Nucl Med; 2015 Feb; 56(2):287-92. PubMed ID: 25552666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients.
    Maréchal R; De Schutter J; Nagy N; Demetter P; Lemmers A; Devière J; Salmon I; Tejpar S; Van Laethem JL
    BMC Cancer; 2010 Jun; 10():340. PubMed ID: 20591136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early FDG/PET scanning as a pharmacodynamic marker of anti-EGFR antibody activity in colorectal cancer.
    Krystal GW; Alesi E; Tatum JL
    Mol Cancer Ther; 2012 Jul; 11(7):1385-8. PubMed ID: 22562987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line single-agent cetuximab in patients with advanced colorectal cancer.
    Pessino A; Artale S; Sciallero S; Guglielmi A; Fornarini G; Andreotti IC; Mammoliti S; Comandini D; Caprioni F; Bennicelli E; Andretta V; Siena S; Sobrero A
    Ann Oncol; 2008 Apr; 19(4):711-6. PubMed ID: 18073221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.